Recruiting Heart Attack Studies in Kansas City
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning ...
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
The primary objective of this study is to evaluate the efficacy of extended release naltrexone plus bupropion XL (XR-NTX/BUP-XL) compared to matched injectable and oral placebo (iPLB/oPLB) in reducing...
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compa...
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA ...
A Study of AT-02 in Subjects With Systemic Amyloidosis.
This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat sys...
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia...
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus...
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis...
About Heart Attack Clinical Trials in Kansas City
A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.
There are currently 8 heart attack clinical trials recruiting participants in Kansas City, KS. These studies are seeking a combined 1,409 participants. Research is being sponsored by Incyte Corporation, National Institute on Drug Abuse (NIDA), Rapamycin Holdings Inc. and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Heart Attack Clinical Trials in Kansas City — FAQ
Are there heart attack clinical trials in Kansas City?
Yes, there are 8 heart attack clinical trials currently recruiting in Kansas City, KS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Kansas City?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Kansas City research site will contact you about next steps.
Are clinical trials in Kansas City free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Kansas City studies also compensate for your time and travel.
What heart attack treatments are being tested?
The 8 active trials in Kansas City are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.
Data updated March 2, 2026 from ClinicalTrials.gov